🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Coming soon... The 12th Edition of Braunwald's Heart Disease. Terrific authors! @bonowr Karen Joynt Maddox Pradeep Natarajan Sharmila Dorbala Marcelo Di Carli Ron Blankstein Dr Roxana Mehran @drmortkern Marc Bonaca MD MPH @JJheart_doc Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 and more! #cardiotwitter #CardioEd bookmark.elsevierhealth.com/preface-to-bra…

⚡️#DELIVER delivers on primary outcome, extending benefits of #SGLT2i dapagliflozin to full spectrum of pts with HF. Looking forward to presenting the data from the largest and broadest RCT of #HFmrEF & #HFpEF at an upcoming meeting.

Looking forward to presenting the results of #DELIVER at Hotline session at ESC on Saturday Aug 27th at 4:30pm CET. Join us in person or virtually!

Stay tuned for the results of #DELIVER to be presented at dedicated Hotline session at ESC today at 4:30pm CET, followed by Pardeep Jhund presenting pooled analysis of DAPA-HF and DELIVER and then Muthu Vaduganathan presenting meta-analysis of DELIVER, EMPEROR-PRESERVED + bonus!

New data from #DELIVER at HFSA - patients with heart failure with improved EF have similar high event rates and benefit from dapagliflozin at least as much as those with LVEF consistently over 40%.

Akshay Desai presented influence of dapagliflozin on causes of death across DAPA-HF and #DELIVER also published in JAMA Cardiology

Applying #DELIVER trial findings to hospitalized Medicare patients in GWTG Muthu Vaduganathan showed at HFSA that 80% would be eligible with an expanded indication and result in 9% absolute risk reduction NNT =11 in HF readmission or death

The #DELIVER team is proud to share 4 new #SimPub as #LBCT/#FS at #HFSA2022 📰Improved LVEF by orlyvardeny in Nature Medicine (in press) 📰Blood Pressure by Senthil Selvaraj, MD, MS, MA in JACC Journals #JACCHF 📰Mode of Death by Akshay Desai in JAMA Cardiology 📰Time to Benefit in JAMA Cardiology

Links to #SimPub Articles with #HFSA2022: Blood Pressure #JACCHF: jacc.org/doi/10.1016/j.… Mode of Death JAMA Cardiology: jamanetwork.com/journals/jamac… Time to Clinical Benefit JAMA Cardiology jamanetwork.com/journals/jamac…

6 new #DELIVER trial presentations at AHA - recurrent events, background MRA/ARNI, Sex differences, COVID-19, effect of dapagliflozin according to RACE, and effects on quality of life. #DELIVER information, manuscripts and presentations available now at delivertrial.org

Ankeet Bhatt presented the #DELIVER Covid-19 data today at AHA. View presentation at delivertrial.org

Dapagliflozin by glycemic status from #DELIVER published today in Lancet Diabetes and Endocrinology secure-web.cisco.com/19Qke4ZlRvmE7C…. Also full #DELIVER publications and presentations at delivertrial.org

Many patients may have improvement in #LVEF w prior medical Rx. New data from #DELIVER = largest RCT data of #HFimpEF #HFimpEF face important residual risks which may be modified w new initiation of #SGLT2i. Published in Nature Medicine by orlyvardeny! nature.com/articles/s4159…

From #DELIVER today, Dapagliflozin in HF with Improved Ejection Fraction, by orlyvardeny in @naturemedicine, nature.com/articles/s4159…, and Dapagliflozin and Health Status and QOL in JACC, jacc.org/doi/10.1016/j.…; delivertrial.org

Proud of our whole research team in finalizing our NUDGE-FLU trial in which we randomized the whole danish population >=65 years to test which NUDGE letter would increase flu vaccine uptake most. Presented at the LBCT at ACC and simultaneously published in The Lancet & Circulation

#NUDGEFLU Nudging a Nation Design & rationale of #NUDGEFLU published in AmericanHeartJ outlines key principles of how unique Danish electronic communication system rapidly and feasibly reached a population. sciencedirect.com/science/articl…

FDA issues extended approval for dapagliflozin based on the #DELIVER trial. astrazeneca.com/media-centre/p…

#ACTIV4a LBCT #ISTH2023 & simpub in Circulation! Major multicenter effort led by scottdavidsolomon testing a fundamental question in pathobiology of #COVID19 #Crizanlizumab (P-selectin inhibitor) did not improve organ-support free days in patients w #COVID19 ahajournals.org/doi/10.1161/CI…

Outstanding Heart Failure Collaboratory-ARC meeting in Miami

I look forward to presenting the final results of FINEARTS-HF at the ESC Sept 1 in London bayer.com/media/en-us/fi…